Interleukin-2 in cancer

Bibliography

• SMITH KA: Interleukin-2: inception, impact and implications. Science (1988) 240:1169–1176.
   PubMed Web of Science ®Google Scholar
• MAZUMDER A, ROSENBERG SA: Successful immuno-therapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.1 Exp. Med. (1984) 159: 495–507.
   Google Scholar
• ROSENBERG SA, MULE JJ, SPIESS PJ, REICHERT CM, SCHVVARZ SL: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.1 Exp. Med. (1985) 161:1169–1188.
   PubMed Web of Science ®Google Scholar
• MULE JJ, SHU S, SCHVVARZ SL, ROSENBERG SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 225:1487–1489.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, YANG JC, et al.: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. (1989) 210(0474–484.
   PubMed Web of Science ®Google Scholar
• THOMPSON JA, LEE DJ, LINDGREN CG, et al.: Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. I Clin. Oncol (1988) 6:669–678.
   Web of Science ®Google Scholar
• ATKINS MB, LOTZE MT, DUTCHER JP, et al.: High-doserecombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.1 Clin. Oncol (1999) 17:2105.
   Google Scholar
• LANDIS SH, MURRAY T, BOLDEN S, WINGO PA: CancerStatistics, 1999. CA Cancer J. Clin. (1999) 49:8–31.
   PubMed Web of Science ®Google Scholar
• De Vita VT, Jr., Hellman S, Rosenberg SA (Eds.), Lippincott-Raven, Philadelphia, USA (1997):1947–1994.
   Google Scholar
• RYAN L, KRAMAR A, BORDEN E: Prognostic factors inmetastatic melanoma. Cancer (1993) 71:2995–3005.
   PubMed Web of Science ®Google Scholar
• GALANIS E, HERSH EM, STOPECK AT, et al.: Irnmuno-therapy of advanced malignancy by direct gene transfer of an in terleukin -2 DNA/DMRIE/DOPE lipid complex: Phase VII experience. J. Clin. Oncol. (1999) 17:3313-3323. (In Process).
   Google Scholar
• NATHAN FE, MASTRANGELO MJ: Systemic therapy in melanoma. Semin. Surg. Oncol. (1998) 14:319–327.
   PubMed Web of Science ®Google Scholar
• HILL GJ, KREMENTZ ET, HILL HZ, et al.: Dimethyltriazeno imidazole carboxamide and combination therapy for melanoma: late results. Cancer (1984) 53:1299–1305.
   PubMed Web of Science ®Google Scholar
• COHEN GL FALKSON CI: Current treatment options for malignant melanoma. Drugs (1998) 55:791–799.
   PubMed Web of Science ®Google Scholar
• THOMPSON DB, ADENA M, MCLEOD GR, et al.: Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res. (1993) 3:133–138.
   PubMed Web of Science ®Google Scholar
• FALKSON CI, FALKSON G, FALKSON HC: Improved results with the addition of interferon alpha-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. I an. Oncol. (1991) 9:1403–1408.
   PubMed Web of Science ®Google Scholar
• KIRKWOOD JM, ERNSTOFF MS, GIULIANO A, et al.: Interferon-2a and dacarbazine in melanoma. J. Nati Cancer Inst. (1990) 82:1062–1063.
   PubMed Web of Science ®Google Scholar
• BAJETTA E, DI LEO A, ZAMPINO MG, et al.: Multicenter randomized trial of dacarbazine alone or in combina-tion of two different doses and schedules of interferon alpha-2a in the treatment of advanced melanoma. J. Clin. Oncol. (1994) 12:806–811.
   PubMed Web of Science ®Google Scholar
• MCCLAY EF, MASTRANGELO MJ, BERD D, et al.: Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int. J. Cancer (1992) 50:553–556.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM (Ed.), Marcel Dekker, New York, USA (1998):219–251.
   Google Scholar
• MULDERS P, TSO CL, PANGS et al.: Adenovirus-mediatedinterleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma. / immunother. (1998) 21:170–180.
   Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, WHITE DE, STEINBERG SM:Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. (1998) 228:307–319.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD RP, KOPECKY KJ, SAMSON MK, et al.: Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study. J. Natl. Cancer Inst. (1991) 83:1250–1252.
   PubMed Web of Science ®Google Scholar
• SPARANO JA, FISHER RI, SUNDERLAND M, et al.: Random-ized Phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alpha-2a in patients with advanced melanoma. J Chn. Oncol. (1993) 11:1969–1977.
   PubMed Web of Science ®Google Scholar
• HERSH EM, MURRAY JL, HONG WK, et al.: Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injection. Biother-apy (1989) 1:215–226.
   PubMedGoogle Scholar
• DEMCHAK PA, MIER JW, ROBERT NJ, O'BRIEN K, GOULD JA, ATKINS MB: Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin. Oncol. (1991) 9:1821–1830.
   PubMed Web of Science ®Google Scholar
• KEILHOLZ U, CONRADT C, LEGHA SS, et al: Results ofinterleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin. Oncol. (1998) 16:2921–2929.
   PubMed Web of Science ®Google Scholar
• SZNOL M, PARKINSON DR: Interleukin-2 in therapy of hematologic malignancies. Blood (1994) 83:2020–2022.
   PubMed Web of Science ®Google Scholar
• GOLD PJ, THOMPSON JA, MARKOWITZ DR, NEUMANN S, FEFER A: Metastatic renal cell carcinoma:long-term survival after therapy with high-dose continuous infusion interleukin-2. Cancer. J. Sci. Am. (1997) 3:S85–S91.
   PubMed Web of Science ®Google Scholar
• WHITE RL JR, SCHWARTZENTRUBE DJ, GULERIA A, et al: Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer (1994) 74:3212–3222.
   PubMed Web of Science ®Google Scholar
• ATKINS MB, SPARANO J, FISHER RI, et al: Randomized Phase II trial of high-dose interleukin-2 either alone or in combination with interferon alpha-2b in advanced renal cell carcinoma. J Clin. Oncol. (1993)11:661-670.
   Google Scholar
• DUTCHER JP, ATKINS M, FISHER R, et al.: Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989–1997. Cancer J. Sci. Am. (1997) 3 (Suppl. 1):S73–S78.
   PubMedGoogle Scholar
• CALIGIURI MA, MURRAY C, SOIFFER RJ, et al.: Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immuno-modulation without significant toxicity. J Clin. Oncol. (1991) 9:2110–2119.
   PubMed Web of Science ®Google Scholar
• LISSONI P: Effects of low-dose recombinantin ter leukin-2 in human malignancies. Cancer/ ScL Am. (1997) 3 (Suppl. 1):S115–S120.
   PubMedGoogle Scholar
• VLASVELD LT, RANKIN EM, HEKMAN A, et al.: A Phase Istudy of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects. Br. J Cancer (1992) 65:744–750.
   PubMed Web of Science ®Google Scholar
• WEST WH, TAUER KW, YANNELLI JR, et al.: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. (1987) 316:898–905.
   PubMed Web of Science ®Google Scholar
• DUTCHER JP, GAYNOR ER, BOLDT DH, et al.: A Phase IIstudy of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J. Clin. Oncol. (1991) 9:641–648.
   PubMed Web of Science ®Google Scholar
• CREEKMORE SP, HARRIS JE, ELLIS TM, et al.: A Phase Iclinical trial of recombinant interleukin-2 by periodic 24- hour intravenous infusions. J Clin. Oncol. (1989) 7:276–284.
   PubMed Web of Science ®Google Scholar
• VLASVELD LT, HORENBLAS S, HEKMAN A, et al.: Phase IIstudy of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. Ann. Oncol (1994) 5:179–181.
   PubMed Web of Science ®Google Scholar
• PEREZ EA, SCUDDER SA, MEYERS FA, TANAKA MS, PARADISE C, GANDARA DR: Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a Phase I study. J Immunother. (1991) 10:57–62.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO, OLDHAM RK, BARTH NM, et al.: Continuousinterleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biother-apy study group trial. Cancer (1991) 68:1–8.
   PubMed Web of Science ®Google Scholar
• LEGHA SS, GIANAN MA, PLAGER C, ETON OE, PAPADO-POULOUS NE: Evaluation of interleukin-2 adminis-tered by continuous infusion in patients with metastatic melanoma. Cancer (1996) 77:89–96.
   PubMed Web of Science ®Google Scholar
• SONDEL PM, KOHLER PC, HANK JA, et al.: Clinical andimmunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res. (1988) 48:2561–2567.
   PubMed Web of Science ®Google Scholar
• VLASVELD LT, HEKMAN A, VYTH-DREESE FA, et al.: Aphase I study of prolonged continous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects. Br. J Cancer (1993) 68:559–567.
   PubMed Web of Science ®Google Scholar
• YANG JC, TOPALIAN SL, PARKINSON D, et al.: Random-ized comparison of high-dose and low-dose intrave-nous interleukin- 2 for the therapy of metastatic renal cell carcinoma: an interim report. j Clin. Oncol (1994) 12:1572–1576.
   PubMed Web of Science ®Google Scholar
• FIGLIN RA, THOMPSON RM, BUKOWSKI NJ, et al.: Multicenter, randomized, Phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. j Clin. Oncol. (1999) 17:2521 (In Process).
   Google Scholar
• TAGLIAFERRI P, BARILE C, CARAGLIA M, et al: Dailylow-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects. Am. J. Clin. Oncol. (1998) 21:48–53.
   PubMed Web of Science ®Google Scholar
• RAVAUD A, AUDHUY B, GOMEZ F, et al.: Subcutaneousinterleukin-2, interferon alpha-2a and continuous infusion of fluor our acil in metastatic renal cell carcinoma: a multicenter Phase II trial. Groupe Francais d'Immunotherapie. j Clin. Oncol. (1998) 16:2728–2732.
   Web of Science ®Google Scholar
• TOURANI JM, PFISTER C, BERDAH JF, et al: Outpatient treatment with subcutaneous interleukin-2 and interferon alpha administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized Phase II study. Subcutaneous Administration Prop eukin Program Cooperative Group. J. Clin. Oncol. (1998)16:2505–2513.
   PubMed Web of Science ®Google Scholar
• RICHARDS JM, GILEWSKI TA, RAMMING K, MITCHEL B, DOANE LL, VOGELZANG NJ: Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer (1992) 69:427–429.
   PubMed Web of Science ®Google Scholar
• LEGHA SS, RING S, ETON O, et al.: Development of a biochemotherapy regimen with concurrent admini-stration of cisplatin, vinblastine, dacarbazine, interferon alpha and in terleukin -2 for patients with metastatic melanoma. J. Gun. Oncol. (1998)1 6 :1752–1759.
   Google Scholar
• RICHARDS JM, GALE D, MEHTA N, LESTINGI T: Combina-tion of chemotherapy with interleukin-2 and interferon alpha for the treatment of metastatic melanoma. J Clin. Oncol. (1999) 17:651–657.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ, et al: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine and tamoxifen alone or in combination with interleukin-2 and interferon alpha-2b. J. Clin. Oncol. (1999) 17:968–975.
   PubMed Web of Science ®Google Scholar
• HELLSTRAND K, HERMODSSON S, NAREDI P, MELLQVIST UH, BRUNE M: Histamine and cytokine therapy. Acta Oncologica (1998) 37:347–353.
   PubMed Web of Science ®Google Scholar
• MCDERMOTT DF, TREHU EG, MIER JW, et al.: A two-part Phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. Clin. Cancer Res. (1998) 4:1203–1213.
   PubMed Web of Science ®Google Scholar
• SOSMAN JA, FISHER SG, KEFER C, FISHER RI, ELLIS TM: A Phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. Ann. Oncol. (1994) 5:447–452.
   PubMed Web of Science ®Google Scholar
• SOSMAN JA, KEFER C, FISHER RI, JACOBS CD, PUMFERY P, ELLIS TM: A Phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients. J Immunother. Emphasis Tumour Immunol. (1995) 1 7:171–180.
   Google Scholar
• SOSMAN JA, WEISS GR, MARGOLIN KA, et al: Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects. J. Clin. Oncol. (1993)11:1496–1505.
   PubMed Web of Science ®Google Scholar
• KRUIT WH, GOEY SH, MONSON JR, et al.: Clinical experi-ence with the combined use of recombinant interleukin-2 (II2) and interferon alpha-2a (IFN alpha) in metastatic melanoma. Br. J Haematol. (1991) 79 (Suppl. 0:84–86.
   PubMedGoogle Scholar
• LEE KH, TALPAZ M, ROTHBERG JM, et al: Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a Phase I study. J. Clin. Onco/.(1989) 7:1726–1732.
   PubMed Web of Science ®Google Scholar
• MITTELMAN A, HUBERMAN M, PUCCIO C, et al.: A Phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer and malignant melanoma. Cancer (1990) 66:664–669.
   PubMed Web of Science ®Google Scholar
• O'DAY SJ, GAMMON G, BOASBERG PD, et al.: Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor and tamoxifen for patients with metastatic melanoma. J. Clin. Oncol. (1999) 17:2752 (In Process).
   Google Scholar
• KONDO M, NONOMURA N, MIKI T, et al: Enhancement of interleukin-2-induced lymphokine-activated killer activity by interleukin 7 against autologous human renal cell carcinoma. Oncology (1998) 55:588–593.
   PubMed Web of Science ®Google Scholar
• RIDOLFI R, FLAMINI E, RICCOBON A, et al.: Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy and in 12 advanced patients. Cancer Immunol. Immunother. (1998) 46:185–193.
   PubMed Web of Science ®Google Scholar
• REALI UM, MARTINI L, BORGOGNONI L, et al.: Infusion of in vitro expanded tumour-infiltrating lymphocytes and recombinant interleukin-2 in patients with surgically resected lymph node metastases of malignant melanoma: a pilot study. Melanoma Res. (1998) 8:77–82.
   PubMed Web of Science ®Google Scholar
• MOGI S, EBATA T, SETOGUCHI Y et al.: Efficient genera-tion of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2. Clin. Cancer Res. (1998) 4:713–720.
   PubMed Web of Science ®Google Scholar
• FENTON RG, TURCOVSKI-CORRALES SM, TAUB DD: Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines. J. Immuno-ther. (1998) 21 :95–108.
   PubMed Web of Science ®Google Scholar
• BELLDEGRUN AL, MUUL M, ROSENBERG SA: Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization and antitumor activity. Cancer Res. (1988) 48:206–214.
   PubMed Web of Science ®Google Scholar
• SPIESS P J, YANG JC, ROSENBERG SA: In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant in terleukin -2. J. Natl. Cancer Inst. (1987) 79:1067–1075.
   Google Scholar
• BELLDEGRUN A, TSO CL, KABOO R, et al.: Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and intherapy. J. Immunother. EmphasisTumour Immunol. (1996) 19:149–161.
   PubMed Web of Science ®Google Scholar
• FINKE JH, RAYMAN P, ALEXANDER J, et al.: Characteriza-tion of the cytolytic activity of CD4+ and CD8+ tumor-infilterating lymphocytes in human renal cell carcinoma. Cancer Res. (1990) 50:2363–2370.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, SCHVVARZ SL, SPIESS PJ: Combinationimmunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alpha interferon and tumor-infiltrating lymphocytes. J. Nati Cancer Inst. (1988) 80:1393–1397.
   PubMed Web of Science ®Google Scholar
• KHATRI V P,BAIOCCHI RA,BERNSTEIN ZP, CALIGIURI MA:Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer. Cancer J. Sci. Am. (1997) 3 (Suppl. 1):S129–S136.
   Google Scholar
• PLAISANCE S, RUBINSTEIN E, ALILECHE A, et al: Humanmelanoma cells express a functional interleukin-2 receptor. Int. J. Cancer (1993) 55:164–170.
   PubMed Web of Science ®Google Scholar
• BAARS JW, WOLBINK GJ, HART MH, et al.: The release ofinterleukin-8 during intravenous bolus treatment with interleukin-2. Ann. Oncol. (1994) 5:929–934.
   PubMed Web of Science ®Google Scholar
• DEEHAN DJ, HEYS SD, SIMPSON WG, BROOM J, FRANKS C, EREMIN O: In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses. Br. J Cancer (1994) 69:1130–1135.
   PubMed Web of Science ®Google Scholar
• LISSONI P, FUMAGALLI L, ROVELLI F, BRIVIO F, DI FELICEG, MAJORCA F: In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients. Br. J Cancer (1998) 77:1957–1960.
   PubMed Web of Science ®Google Scholar
• WEIDMANN E, BERGMANN L, STOCK J, KIRSTEN R, MITROU PS: Rapid cytokine release in cancer patients treated with interleukin-2. J. Immunother. (1992) 12:123–131.
   PubMed Web of Science ®Google Scholar
• BAARS J, WAGSTAFF WJ, HACK CE, et al.: Angioneuroticoedema and urticaria during therapy with in ter leukin-2 (IL-2). Ann. Oncol. (1992) 3:243–244.
   PubMed Web of Science ®Google Scholar
• BECKER JC, DUMMER R, SCHWINN A: Circulatingintercellular adhesion molecule-1 in melanoma patients: induction by interleukin-2 therapy. J. Immunother. (1992) 12:147–150.
   PubMed Web of Science ®Google Scholar
• JANSSON OT, MORCOS E, RUNDIN L, et al.: Nitric oxide synthase activity in human renal cell carcinoma. J Urol. (1998) 160:556–560.
   PubMed Web of Science ®Google Scholar
• ANDERSON CM, BUZAID AC, SUSSMAN J, et al.: Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Res. (1998) 8:149–155.
   PubMed Web of Science ®Google Scholar
• KAMMULA US,WHITE DE, ROSENBERG SA: Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer (1998) 83:797–805.
   PubMed Web of Science ®Google Scholar
• Muggia FM (Ed.), Kluwer Academic Publishers, Boston, MA, USA (1995):3–27.
   Google Scholar
• SMITH KA: Rational interleukin-2 therapy. Cancer J. Sci. Am. (1997) 3 (Suppl. 0:5137–S140.
   Google Scholar
• ROSENBERG SA, YANG JC, TOPALIAN SL, et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 271 :907–913.
   PubMed Web of Science ®Google Scholar
• FISCHER RI, ROSENBURG SA, SZNOL M, PARKINSON DR,FYFE G: High-dose aldesleukin in renal cell carcinoma: long term survival update. Cancer J Sci. Am. (1997) 3:S70–S72.
   PubMed Web of Science ®Google Scholar
• YANG JC, ROSENBERG SA: An ongoing prospectiverandomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer./ Sci. Am. (1997) 3:S79–S84.
   PubMed Web of Science ®Google Scholar